Astellas Pharma (OTCPK:ALPMF) and collaboration partner Pfizer (NYSE:PFE) announce final overall survival (OS) data from a Phase 3 clinical trial, PROSPER,
evaluating Xtandi (enzalutamide) plus androgen deprivation therapy
(ADT) in men with non-metastatic castration-resistant prostate cancer.
Treatment with Xtandi + ADT resulted in a
statistically significant improvement in OS, a secondary endpoint,
compared to placebo + ADT.
In September 2017, the companies announced that the study met the primary endpoint of metastasis-free survival.
https://seekingalpha.com/news/3540490-xtandi-extends-survival-in-late-stage-prostate-cancer-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.